Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.
about
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroOptimal drug synergy in antimicrobial treatmentsExpression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expressionLung infections associated with cystic fibrosis.marA, a regulated locus which controls expression of chromosomal multiple antibiotic resistance in Escherichia coli.Cloning and nucleotide sequence of the DNA gyrase gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant clinical isolatesEnergy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains.Resistance emerging after pefloxacin therapy of experimental Enterobacter cloacae peritonitis.Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.Efflux-mediated resistance to fluoroquinolones in gram-negative bacteriaBacterial resistance to penicillin G by decreased affinity of penicillin-binding proteins: a mathematical modelAlternating antibiotic treatments constrain evolutionary paths to multidrug resistanceIn vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.Point mutation in the pribnow box, the molecular basis of beta-lactamase overproduction in Klebsiella oxytocaIn vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins.The population dynamics of antimicrobial chemotherapy.Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon.Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacinActivities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.Purification of Citrobacter freundii DNA gyrase and inhibition by quinolonesMutation of Salmonella paratyphi A conferring cross-resistance to several groups of antibiotics by decreased permeability and loss of invasivenessGenetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacinIn vitro activities of amifloxacin and two of its metabolites.beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.Outer membrane barrier as a mechanism of antimicrobial resistance.Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance.Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.Adaptive resistance to biocides in Salmonella enterica and Escherichia coli O157 and cross-resistance to antimicrobial agentsEfficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.Activation of multiple antibiotic resistance and binding of stress-inducible promoters by Escherichia coli Rob protein.Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients
P2860
Q24670241-55E49C0A-AFCA-417A-91E3-E345C5D4ACCEQ28474170-DF5C7E7C-37DE-45EF-B2A9-F15FAFC0A196Q28492894-1F3CE118-67E0-4EAB-A74B-6978F94D0501Q30080000-C31C9C3E-F1AF-4935-9177-802BCE8505B5Q33266090-16092873-6929-4E38-B2C7-32B4BAC67AFFQ33690745-86589ED3-CE13-4198-B33F-3FC164E044AAQ33694558-D26E7B76-A239-4161-8DFF-E02EF4A2DD85Q33742745-97AC0DC0-23D8-4B5C-A46B-123EF5B3953FQ33938255-CD4BBC7E-0906-4557-A24D-E0BA16978C4CQ34010692-B912ED12-B68C-4496-BD95-F1A6D0EB9BE7Q34215950-07EFAC28-5B28-4755-A85B-A23497FABA0DQ34407557-54108988-5D1D-431D-B7B3-F71841E88A85Q34622742-8340A3C7-F5B3-4820-B09D-B2DEFE35218EQ34687048-91273048-3F92-413C-8A26-04FAD24DB3B0Q35114789-A05E3A62-1CCB-48AC-A374-F3DDDABE8A2EQ35115498-BFAA5152-6059-4A9E-B6CE-75AA442D09ADQ35122321-661D1C0A-C290-4E71-A985-5FABB521E744Q35132378-07BA9FE1-C7C1-45FD-A378-142F8F16628EQ35138349-C4F59BE2-1521-44D7-BFBC-147BE5400A30Q35243870-14B19610-CC05-4595-ACD3-2082A86D4E77Q35245733-4DD8ACA4-10B4-4D91-8A92-15C33DFFAD71Q35260514-C48CB0A9-9E78-4EC9-8B2A-6457EA8EA0EBQ35289324-6AEA2991-2E60-4A16-9013-DCB3D76AFE2EQ35291408-BE4810FB-8475-4251-A58B-F7E5ADAF31BBQ35299812-EC280302-9292-4C66-92B9-711190919AB7Q35319641-5CD3F20A-090C-40AD-9D38-CB97E64DBF91Q35334146-AA585A06-727D-4BBF-B64B-B677057D0566Q35343778-20F602F0-F800-4905-8781-9826474DD6EDQ35357625-D213BDFE-CB4A-4BA2-B5A8-B4363A600A07Q35474783-0779FDDD-F628-4E7B-98C5-6274FAC7C769Q35536165-2B948722-5656-4426-B97E-955737D2E10BQ35536186-46DFAA3F-5605-4BAF-A741-F411C34DEDDCQ35543422-42041A5E-D946-4839-867F-D5F8A8828549Q35543537-A5F1D10F-AE6F-48BF-AE45-0E1BFCEF0065Q35551972-4D6AC5AE-F952-4599-8FF3-8A9136342200Q35574922-C73C1F6D-6BE8-4500-BD75-07ECEDE6C371Q35581659-97FA0781-C0A3-44E7-83FE-A5DCBA253951Q35650708-5AF9F88C-22AA-43B0-8514-C5D1875332CEQ35811107-6D6075F6-44ED-438A-9F4B-E780E1126FAFQ35823963-7B2CC6F0-81CB-43FD-8736-B053F73703C8
P2860
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Selection of multiple antibiot ...... etween unrelated drug classes.
@ast
Selection of multiple antibiot ...... etween unrelated drug classes.
@en
type
label
Selection of multiple antibiot ...... etween unrelated drug classes.
@ast
Selection of multiple antibiot ...... etween unrelated drug classes.
@en
prefLabel
Selection of multiple antibiot ...... etween unrelated drug classes.
@ast
Selection of multiple antibiot ...... etween unrelated drug classes.
@en
P2093
P2860
P356
P1476
Selection of multiple antibiot ...... between unrelated drug classes
@en
P2093
C C Sanders
W E Sanders
P2860
P304
P356
10.1128/AAC.26.6.797
P407
P577
1984-12-01T00:00:00Z